Immunotherapy for Malignant Mesothelioma
Immunotherapy for Malignant Mesothelioma
批准号:
7592963
负责人:
RAFFIT HASSAN
金额:
$66.12万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AdoptedAgonistAttenuatedBacteriaBindingCA-125 AntigenCancer VaccinesCell LineCisplatinClinicClinicalClinical TrialsCollaborationsConduct Clinical TrialsCytolysisDifferentiation AntigensDoseDose-LimitingDrug KineticsDrug usageEnd PointEnrollmentEnzyme-Linked Immunosorbent AssayEpitopesExhibitsGoalsHumanImmune responseImmunityImmunotherapyImmunotoxinsInstitutionInterventionLaboratoriesLaboratory ResearchLaboratory StudyLeadLifeLinkListeria monocytogenesLungLung AdenocarcinomaMacaca fascicularisMalignant NeoplasmsMalignant mesotheliomaMalignant neoplasm of pancreasMaximum Tolerated DoseMeasurementMediatingMesothelial CellMesotheliomaMonoclonal AntibodiesMusOutcomeOvarianPaclitaxelPancreasPancreatic AdenocarcinomaPatientsPemetrexedPeritoneumPhasePhase I Clinical TrialsPhase II Clinical TrialsPlayPleuraPleural MesotheliomaProcessProteinsPseudomonas aeruginosa toxA proteinRandomizedRecombinantsResearchResearch PersonnelSafetyScientistSignal TransductionSiteStagingT-LymphocyteTestingToxic effectTranslational ResearchTreatment EfficacyTumor AntigensTumor Cell LineUnresectableVaccine TherapyWorkXenograft Modelantibody-dependent cell cytotoxicitybasecancer therapychemotherapeutic agentchemotherapyconceptgemcitabinehuman tissueimmunogenicimprovedmesothelinneoplastic cellnovelpericardial sacpreclinical studyprogramsprotocol developmentsuccesstumortumor growthtumor xenograftvector
中文摘要
由于使用化疗治疗间皮瘤的经典干预措施取得的成功有限,我们选择通过靶向肿瘤分化抗原来治疗间皮瘤。我们目前的研究集中在针对LMB中发现的一种肿瘤抗原--间皮蛋白的免疫治疗上。在正常人体组织中,间皮蛋白的表达仅限于胸膜、心包和腹膜内的间皮细胞,而在多种人类肿瘤中,尤其是间皮瘤、卵巢癌、肺癌和胰腺癌中表达较高。这种不同的表达使其成为肿瘤特异性治疗的候选药物。在确认间皮素作为癌症治疗的靶点后,我们现在的努力集中在利用它进行间皮瘤治疗,使用不同作用机制的药物。我们目前正在评估三种间皮素靶向药物治疗间皮瘤。其中两种试剂CAT-5001(SS1P)和MORAB-009正在临床使用,第三种药物CRS-207即将进入I期测试。CAT-5001是一种重组免疫毒素,由与截短的假单胞菌外毒素A相连的抗间皮蛋白抗体组成。我们最近完成了CAT-5001在表达间皮蛋白的癌症患者中的I期临床试验。我们建立了CAT-5001的最大耐受量(MTD)、剂量限制毒性(DLT)、药代动力学,并观察了一组接受大量预治疗的患者的抗肿瘤活性。在确定CAT-5001的安全性和耐受性后,我们现在计划评估它在间皮瘤中的疗效。我们采用的策略是联合CAT-5001、培美曲塞和顺铂作为不能切除的胸膜间皮瘤患者的一线治疗方案。这项研究的基本原理是基于我们的实验室研究,这些研究表明CAT-5001和几种化疗药物在肿瘤异种移植模型中具有显着的协同作用。我们正在评估的治疗间皮瘤的第二种间硫蛋白靶向药物是MORAb-009,这是一种嵌合的抗间硫蛋白单抗,是LMB和MorPhotek Inc.合作开发的。在临床前研究中,MORAb-009介导了对表达间硫蛋白的肿瘤细胞的抗体依赖细胞毒性(ADCC),抑制了间硫蛋白与CA-125的结合,并导致肿瘤生长抑制。我们目前正在进行一项MORAb-009的三机构I期临床试验,对象是表达间皮素的癌症患者,NCI只有间皮瘤患者参加了这项研究。我的实验室的研究表明,MORAb-009与吉西他滨和紫杉醇联合使用时,抗肿瘤效果显著增强。基于这些结果,一项关于MORAb-009联合吉西他滨与单用吉西他滨治疗晚期胰腺癌的多机构II期随机研究即将开始。此外,在正在进行的第一阶段剂量递增研究完成后,我们正在启动MORAb-009用于恶性间皮瘤化疗的第二阶段研究。我们的团队和其他研究人员已经确定间甲硫蛋白是疫苗治疗的靶点,因为它是一种免疫原性蛋白,可以在患者中引起体液和细胞免疫反应。我们还鉴定了间硫蛋白的免疫原性表位,并表明T细胞系来自天然或激动剂间硫蛋白表位,从而裂解表达间硫蛋白的肿瘤细胞系。我们正在启动CRS-207的I期临床试验,CRS-207是由Cerus Corp.的科学家开发的一种间硫蛋白肿瘤疫苗。CRS-207(LmΔ;Acta/Δ;inlB/hMeso)是一种肿瘤疫苗,它使用活减毒的单核细胞增生性李斯特菌菌株作为载体,编码人类间硫蛋白。临床前研究表明,CRS-207能在小鼠和食蟹猴体内诱导人类间皮蛋白特异性的CD4+/CD8+免疫,并对荷瘤小鼠显示出治疗效果。与Cerus公司合作,我们在CRS-207方案的开发中发挥了重要作用,因为它与间皮瘤患者有关。这项临床试验将是2-3个机构的I期研究,目前正在NCI进行科学审查。NCI网站将招募间皮瘤患者,目标是获得安全和有效的信号,随后可能导致间皮瘤的II期临床试验。这项研究的翻译终点是测量CRS-207治疗前后对间皮质素的体液免疫反应,并将使用我们实验室开发的ELISA进行评估。我们小组在将间甲肾上腺素定义为癌症治疗的靶点以及开发的治疗方法方面发挥了重要作用,我们现在正在临床上对这些药物进行评估。我的团队结合Pastan实验室的基础实验室研究所做的临床和转化性研究使我们能够将间充质素靶向的概念从替补席上带到临床。除了为间皮瘤患者带来新的治疗选择外,我们的研究还可能对卵巢癌、胰腺癌和肺腺癌等高表达间皮瘤的常见癌症的治疗产生影响。
英文摘要
Since classical interventions using chemotherapy for the treatment of mesothelioma have met with limited success we have elected to approach mesothelioma therapy by targeting tumor differentiation antigens. Our current studies are focused on using immunotherapy directed against mesothelin, a tumor antigen identified in LMB. Mesothelin expression in normal human tissues is limited to mesothelial cells lining the pleura, pericardium and peritoneum but it is highly expressed in several human tumors especially mesothelioma, ovarian, lung and pancreatic adenocarcinomas. This differential expression of mesothelin makes it an attractive candidate for tumor specific therapy. Having validated mesothelin as a target for cancer therapy our efforts are now focused on exploiting it for mesothelioma therapy using drugs that act by different mechanisms. We are presently evaluating three mesothelin targeted agents in mesothelioma. Two of these agents, CAT-5001 (SS1P) and MORAb-009 are in the clinic and the third agent CRS-207 is about to enter phase I testing. CAT-5001 is a recombinant immunotoxin consisting of an anti-mesothelin Fv linked to a truncated Pseudomonas exotoxin A. We recently completed a phase I clinical trial of CAT-5001 in patients with mesothelin expressing cancers. We established the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics of CAT-5001 and observed anti-tumor activity in a group of heavily pre-treated patients enrolled on this study. Having established the safety and tolerability of CAT-5001 we now plan to evaluate its efficacy in mesothelioma. The strategy we have adopted is to combine CAT-5001 with pemetrexed and cisplatin as front line therapy for patients with unresectable pleural mesothelioma. The rationale for this study is based on our laboratory studies that show marked synergy between CAT-5001 and several chemotherapeutic agents in tumor xenograft models. The second mesothelin targeted agent we are evaluating for mesothelioma therapy is MORAb-009, a chimeric anti-mesothelin monoclonal antibody that was developed as collaboration between LMB and Morphotek Inc. In pre-clinical studies MORAb-009 mediates antibody-dependent cellular cytotoxicity (ADCC) against mesothelin-expressing tumor cells, inhibits mesothelin binding to CA-125 and leads to tumor growth inhibition. We are currently conducting a three institution phase I clinical trial of MORAb-009 in patients with mesothelin-expressing cancers and only patients with mesothelioma have been enrolled on this study at the NCI. Studies by my laboratory have shown that the anti-tumor efficacy of MORAb-009 is markedly increased in combination with gemcitabine and taxol. Based on these results a multi-institutional phase II randomized study of MORAb-009 with gemcitabine versus gemcitabine alone is about to open in advanced pancreatic cancer. In addition, we are in the process of initiating a phase II study of MORAb-009 with chemotherapy in malignant mesothelioma after the completion of the ongoing phase I dose-escalation study. Our group and other investigators have identified mesothelin as a target for vaccine therapy since it is an immunogenic protein that elicits both humoral and cellular immune response in patients. We have also identified the immunogenic epitopes of mesothelin and showed that T-cell lines derived from the native or the agonist mesothelin epitope lyse mesothelin expressing tumor cell lines. We are initiating a phase I clinical trial of CRS-207, a mesothelin tumor vaccine developed by scientists at Cerus Corp. CRS-207 (LmΔactA/ΔinlB/hMeso) is a tumor vaccine that utilizes a live-attenuated strain of the bacterium Listeria Monocytogenes (Lm) as the vector and encodes human mesothelin. Pre-clinical studies show that CRS-207 elicits human mesothelin-specific CD4+/CD8+ immunity in mice and in cynomolgus monkeys and exhibits therapeutic efficacy in tumor bearing mice. Working with Cerus Corp. we played an important part in protocol development of CRS-207 as it relates to patients with mesothelioma. This clinical trial which will be a 2-3 institution phase I study is currently undergoing scientific review at the NCI. The NCI site will enroll patients with mesothelioma, with the goal of getting safety and efficacy signals that could subsequently lead to a phase II clinical trial in mesothelioma. A translational endpoint of this study is measurement of humoral immune response to mesothelin before and after CRS-207 treatment and will be evaluated using an ELISA developed in our laboratory. Our group has been instrumental in defining mesothelin as a target for cancer therapy as well as developed therapies that we are now evaluating in the clinic. The clinical and translational research done by my group in conjunction with basic laboratory research of the Pastan laboratory has allowed us to take the concept of mesothelin targeting from the bench to the clinic. Besides leading to new treatment options for patients with mesothelioma our research could have implications for the treatment of common cancers such as ovarian, pancreatic and lung adenocarcinomas that highly express mesothelin
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical evaluation of an anti-mesothelin immunotoxin
-
批准号:6436662
-
项目类别:
-
资助金额:$2.36万
-
财政年份:2002
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
-
批准号:9343710
-
项目类别:
-
资助金额:$99.51万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma and Lung Cancer
-
批准号:10702415
-
项目类别:
-
资助金额:$201.88万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:8349180
-
项目类别:
-
资助金额:$79.89万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:7965714
-
项目类别:
-
资助金额:$72.51万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Targeted Therapy of Mesothelioma and Development of Bloo
-
批准号:7338579
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:8552843
-
项目类别:
-
资助金额:$91.48万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:8763233
-
项目类别:
-
资助金额:$94.79万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Thoracic and Gastrointestinal Oncology Branch Medical Clinical Core
-
批准号:8938530
-
项目类别:
-
资助金额:$74.11万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Thoracic and Gastrointestinal Oncology Branch Medical Clinical Core
-
批准号:9556880
-
项目类别:
-
资助金额:$189.03万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma and Lung Cancer
-
批准号:10262161
-
项目类别:
-
资助金额:$186.53万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
-
批准号:10262804
-
项目类别:
-
资助金额:$135.08万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
-
批准号:10014453
-
项目类别:
-
资助金额:$150.66万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
-
批准号:10703109
-
项目类别:
-
资助金额:$146.19万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:8157476
-
项目类别:
-
资助金额:$81.0万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma and Lung Cancer
-
批准号:10926075
-
项目类别:
-
资助金额:$214.86万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
-
批准号:10926685
-
项目类别:
-
资助金额:$155.59万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma
-
批准号:7733250
-
项目类别:
-
资助金额:$59.58万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
-
批准号:8937855
-
项目类别:
-
资助金额:$126.18万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
Targeted therapy of mesothelin expressing cancers using
-
批准号:7291852
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:RAFFIT HASSAN
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: